China's emerging vaccine industry.
The Chinese vaccine industry is developing rapidly due to an emerging and large market for current and new vaccines, a large potential for local vaccine manufacturing both in the public and private domain, and a governmental orientation towards national vaccine self-sufficiency. There are currently over 40 companies and institutions manufacturing a large variety of traditional (EPI) and some new vaccines. The innovative development capacity of state vaccine institutions is stimulated by significant government investments. Various Chinese influenza manufacturers were in 2009 among the first worldwide to obtain national license for their pandemic H1N1 flu vaccines. It is of interest to note that private but also governmental entities are committed to raise manufacturing quality standards to reach WHO prequalification. It is expected that WHO prequalification for at least one product from a Chinese manufacturer will have been obtained by 2011. This will open the door to the global market for Chinese vaccines.
Netherlands Vaccine Institute, Bilthoven, The Netherlands. jan.hendriks@nvi-vaccin.nl
Jan
J
Hendriks
Yan
Y
Liang
Bing
B
Zeng
D002681:China; D003141:Communicable Diseases / Q000453:epidemiology*; D004345:Drug Industry / Q000639:trends*; D006291:Health Policy; D006801:Humans; D014611:Vaccination / Q000706:statistics & numerical data*; D014612:Vaccines / Q000008:administration & dosage*
D014612:Vaccines